Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart drug entresto under safety watch in kids

NCT ID NCT06659393

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 29 times

Summary

This study follows 30 children aged 1 to 18 with chronic heart failure who are taking Entresto for the first time. Researchers will monitor safety issues like low blood pressure, high potassium, kidney problems, and dehydration for up to 52 weeks. The goal is to understand how safe the drug is in real-world use for children.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PEDIATRIC CHRONIC HEART FAILURE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

Locations

  • Novartis Investigative Site

    RECRUITING

    Ōbu, Aichi-ken, 474 8710, Japan

  • Novartis Investigative Site

    RECRUITING

    Toyoake, Aichi-ken, 4701192, Japan

  • Novartis Investigative Site

    RECRUITING

    Kurume, Fukuoka, 830-0011, Japan

  • Novartis Investigative Site

    RECRUITING

    Kurume, Fukuoka, 830-8543, Japan

  • Novartis Investigative Site

    RECRUITING

    Sapporo, Hokkaido, 060-8648, Japan

  • Novartis Investigative Site

    RECRUITING

    Tsukuba, Ibaraki, 3058576, Japan

  • Novartis Investigative Site

    RECRUITING

    Kawasaki, Kanagawa, 2168511, Japan

  • Novartis Investigative Site

    RECRUITING

    Yokohama, Kanagawa-ku, 236-0004, Japan

  • Novartis Investigative Site

    RECRUITING

    Tsu, Mie-ken, 514-8507, Japan

  • Novartis Investigative Site

    RECRUITING

    Nagasaki, Nagasaki, 852-8501, Japan

  • Novartis Investigative Site

    RECRUITING

    Ōmura, Nagasaki, 856-8562, Japan

  • Novartis Investigative Site

    RECRUITING

    Hidaka, Saitama, 350-1298, Japan

  • Novartis Investigative Site

    RECRUITING

    Saitama, Saitama, 330-8777, Japan

  • Novartis Investigative Site

    RECRUITING

    Hamamatsu, Shizuoka, 430-8558, Japan

  • Novartis Investigative Site

    RECRUITING

    Bunkyo Ku, Tokyo, 113-8655, Japan

  • Novartis Investigative Site

    RECRUITING

    Bunkyo Ku, Tokyo, 1138431, Japan

  • Novartis Investigative Site

    RECRUITING

    Bunkyo-ku, Tokyo, 113-8603, Japan

  • Novartis Investigative Site

    RECRUITING

    Fuchū, Tokyo, 183-0003, Japan

  • Novartis Investigative Site

    RECRUITING

    Fuchū, Tokyo, 1838561, Japan

  • Novartis Investigative Site

    RECRUITING

    Ōta-ku, Tokyo, 143 8541, Japan

  • Novartis Investigative Site

    RECRUITING

    Setagaya-ku, Tokyo, 1578535, Japan

  • Novartis Investigative Site

    RECRUITING

    Shinagawa-ku, Tokyo, 1428666, Japan

  • Novartis Investigative Site

    RECRUITING

    Shinjuku Ku, Tokyo, 1628666, Japan

  • Novartis Investigative Site

    RECRUITING

    Toyama, Toyama, 9300194, Japan

  • Novartis Investigative Site

    RECRUITING

    Akita, 010-8543, Japan

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Fukuoka, 8128582, Japan

  • Novartis Investigative Site

    COMPLETED

    Kumamoto, 862-8505, Japan

  • Novartis Investigative Site

    RECRUITING

    Okayama, 7008558, Japan

Conditions

Explore the condition pages connected to this study.

PEDIATRIC CHRONIC HEART FAILURE